Clinical Trial Update: Real-World Treatment Pattern and Clinical Outcome With Influential Factors of HR+/HER2-aBC 1L Patients in China

View source ↗

Summary

A registry-like real-world study in China evaluating first-line treatment patterns and outcomes for HR+/HER2- advanced or metastatic breast cancer, sponsored by…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: HR+/HER2- Advanced or Metastatic Breast Cancer | Status: RECRUITING